Iconovo (OM:ICO) - Aandelenkoers, Nieuws & Analyse

ICO Overzicht aandelen

Iconovo AB (publ) ontwikkelt en licenseert inhalatiemedicijnen in Zweden. Meer informatie

ICO fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 89.5% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 56.26% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( SEK80M )

Heeft minder dan 1 jaar cash runway

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 2 meer risico's

Iconovo AB (publ) Concurrenten

Q-linea

OM:QLINEA

SEK 132.3m

ScandiDos

OM:SDOS

SEK 93.5m

Odinwell

NGM:ODIN

SEK 66.2m

Glycorex Transplantation

NGM:GTAB B

SEK 144.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Iconovo
Historische aandelenkoersen
Huidige aandelenkoers	SEK 5.02
52 Week Hoogtepunt	SEK 12.55
52 Week Laag	SEK 4.15
Bèta	0.75
11 maand verandering	-3.46%
3 maanden verandering	-42.43%
1 Jaar Verandering	-46.25%
33 jaar verandering	-93.71%
5 jaar verandering	-91.96%
Verandering sinds IPO	-86.06%

Recent nieuws en updates

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Rendement voor aandeelhouders

	ICO	SE Medical Equipment	SE Markt
7D	-1.6%	-5.8%	-2.4%
1Y	-46.3%	-7.8%	10.9%

Rendement versus industrie: ICO presteerde slechter dan de Swedish Medical Equipment -sector, die het afgelopen jaar een rendement van -7.8 % opleverde.

Rendement versus markt: ICO presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 10.9 % opleverde.

Prijsvolatiliteit

Is ICO's price volatile compared to industry and market?
ICO volatility
ICO Average Weekly Movement	9.8%
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van ICO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van ICO is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swedish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	28	Johan Waborg	www.iconovo.se

Iconovo AB (publ) ontwikkelt en licenseert inhalatiemedicijnen in Zweden. Het bedrijf biedt ICOres, een flexibele droge poederinhalator met meerdere doses; ICOcap, een droge poederinhalator op basis van capsules; ICOone, een wegwerpbare droge poederinhalator met één dosis; en ICOpre, een vooraf gedoseerde droge poederinhalator; en ICOone Nasal droge poederinhalator met één dosis voor nasaal gebruik. Het bedrijf levert aan generieke bedrijven.

Iconovo AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Iconovo zich tot de beurswaarde?
ICO fundamentele statistieken
Marktkapitalisatie	SEK 79.91m
Inkomsten(TTM)	-SEK 40.20m
Inkomsten(TTM)	SEK 24.99m

3.2x

P/S-verhouding

-2.0x

Koers/Winstverhouding

Is ICO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ICO resultatenrekening (TTM)
Inkomsten	SEK 24.99m
Kosten van inkomsten	SEK 6.44m
Brutowinst	SEK 18.55m
Overige uitgaven	SEK 58.75m
Inkomsten	-SEK 40.20m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 27, 2025

Winst per aandeel (EPS)	-2.53
Brutomarge	74.22%
Nettowinstmarge	-160.91%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ICO op de lange termijn?

Bekijk historische prestaties en vergelijking

ICO Overzicht aandelen

Beloningen

Risicoanalyse

Iconovo AB (publ) Concurrenten

OM:QLINEA

SEK 132.3m

OM:SDOS

SEK 93.5m

NGM:ODIN

SEK 66.2m

NGM:GTAB B

SEK 144.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus revenue estimates decrease by 46%, EPS upgraded

Price target decreased by 22% to kr16.75

Iconovo AB (publ) has completed a Composite Units Offering in the amount of SEK 28.653075 million.

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Recent updates

Consensus revenue estimates decrease by 46%, EPS upgraded

Price target decreased by 22% to kr16.75

Iconovo AB (publ) has completed a Composite Units Offering in the amount of SEK 28.653075 million.

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation